Das SRL Exhibits New Lab Solutions at MEDLAB 2017
|
By LabMedica International staff writers Posted on 09 Feb 2017 |

Image: The AP22 IF BLOT ELITE system (Photo courtesy of Das SRL).
Das SRL, which designs, manufactures, and markets analyzers and automated equipment for application in immuno-enzimatic, immuno-fluorescence, and clinical chemistry, exhibited its AP22 IF BLOT ELITE system and NEO BIL Plus bilirubinometer at MEDLAB 2017.
Italy-based Das SRL offers systems for automated ELISA process on micro-plates and immunofluorescence on slides; readers and washers for laboratories using micro-titre plates or micro-strips; programmable semi-automated photometers for clinical chemistry analysis; and neonatal bilirubinometers for bilirubin monitoring using centrifuged whole blood samples.
The company’s AP22 IF BLOT ELITE is a fully automated system for ELISA and IFA and BLOT methods. The instrument is capable of running 2 ELISA micro-plates with 8 tests on line, 16 IFA slides or 24 BLOT strips. It can perform full automation for the Dot/Western Blot, from sample dilution and dispensing, reagent dispensing, incubation, and strip washing to dot imaging processing and assessment for each strip.
Also on display at the 4-day exhibition held from February 6-9, 2017, in Dubai, UAE was Das SRL’s NEO BIL Plus, an advanced version of traditional bilirubinometers, designed to analyze the 'total bilirubin' through a microcapillary tube. NEO BIL Plus features a special reading system, which can carry out a precise sample measurement of both bilirubin and interferentials at the same point of the capillary using a small quantity of serum and without any reagents.
Italy-based Das SRL offers systems for automated ELISA process on micro-plates and immunofluorescence on slides; readers and washers for laboratories using micro-titre plates or micro-strips; programmable semi-automated photometers for clinical chemistry analysis; and neonatal bilirubinometers for bilirubin monitoring using centrifuged whole blood samples.
The company’s AP22 IF BLOT ELITE is a fully automated system for ELISA and IFA and BLOT methods. The instrument is capable of running 2 ELISA micro-plates with 8 tests on line, 16 IFA slides or 24 BLOT strips. It can perform full automation for the Dot/Western Blot, from sample dilution and dispensing, reagent dispensing, incubation, and strip washing to dot imaging processing and assessment for each strip.
Also on display at the 4-day exhibition held from February 6-9, 2017, in Dubai, UAE was Das SRL’s NEO BIL Plus, an advanced version of traditional bilirubinometers, designed to analyze the 'total bilirubin' through a microcapillary tube. NEO BIL Plus features a special reading system, which can carry out a precise sample measurement of both bilirubin and interferentials at the same point of the capillary using a small quantity of serum and without any reagents.
Latest MEDLAB 2017 News
- AXA Diagnostics Showcases SkyLAB752 ELISA Analyzer
- Norma Diagnostika Showcases Icon Hematology Analyzers at MEDLAB
- AITbiotech Exhibits abTES Molecular Diagnostics Assays at MEDLAB 2017
- Binding Site Unveils Optilite Protein System
- Priorclave Showcases Energy-Efficient Lab Autoclaves in Dubai
- Diatron Exhibits Abacus 5 and Aquila Hematology Analyzers
- DRG Group Presents New Analyzer and ELISAs at Dubai Lab Exhibition
- Beckman Coulter Exhibits New Lab Solutions in Dubai
- Siemens Healthineers Showcases Latest Diagnostic Innovations
Channels
Clinical Chemistry
view channel
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Blood-Based Epigenetic Signals Enable Osteosarcoma Disease Monitoring
Osteosarcoma is a rare but aggressive pediatric bone cancer where recurrence and metastasis remain difficult to detect early. Imaging-based surveillance can miss small lesions and exposes children to repeated... Read more
Host–Virus Genetic Interactions Drive Nasopharyngeal Cancer Risk
Epstein–Barr virus (EBV) infects more than 95% of adults worldwide, yet only a small fraction develops EBV‑associated cancers such as nasopharyngeal carcinoma. Explaining this divergence requires understanding... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreImmunology
view channel
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read moreMicrobiology
view channelRapid Color Test Stratifies Virulent and Resistant Staph Strains
Staphylococcus aureus (golden staph) remains a leading cause of infection-related mortality worldwide, responsible for more than a million deaths each year. Rapidly distinguishing highly virulent or a... Read more
Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance determinants to guide therapy, yet laboratories often face pressure to deliver clinically relevant results quickly... Read more
RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
Human skin carries diverse microbial communities that influence barrier function and inflammation, yet identifying which organisms are metabolically active has been challenging. DNA-based surveys catalog... Read more
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read morePathology
view channel
Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
Colorectal cancer is common and often lethal, and therapeutic decision-making is complicated by heterogeneous tumor microenvironments. Immunotherapy benefits only a small subset of patients, around 5%,... Read more
Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
Antibody-drug conjugates (ADC) are reshaping oncology, yet scalable biomarkers that reliably predict which patients will benefit remain limited as treatment regimens and combinations grow more complex.... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring
Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more








